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Abstract Background and Objectives: GLPG0259 is a small-molecule inhibitor of
mitogen-activated protein kinase–activated protein kinase 5 (MAPKAPK5),
a kinase enzyme that plays a role in important inflammatory pathways. The
main objectives of the phase I clinical studies in early development were to
characterize the pharmacokinetics, tolerability, and safety of GLPG0259 in
healthy subjects, including the development of a solid dosage form (free-base
pellets and fumarate salt capsules) and the potential for interaction of
GLPG0259 with methotrexate.
Subjects and Methods: Four phase I studies were initiated. Study 1 was a
randomized, double-blind, placebo-controlled study to evaluate the safety,
tolerability, and pharmacokinetics of single ascending doses (1.5–150mg)
and multiple oral doses (20 and 50mg once daily) of GLPG0259 in healthy
male subjects (n = 34). Study 2 was a randomized, double-blind, placebo-
controlled study to evaluate the safety, tolerability, and pharmacokinetics of
oral multiple ascending doses of GLPG0259 (25–75mg once daily) given for
14 days to healthy male subjects, and to get preliminary information on the
potential pharmacokinetic interaction between GLPG0259 and methotrexate
(n= 24). Studies 3 and 4 were open-label, randomized, crossover studies to
compare the oral bioavailability of two solid dosage forms of GLPG0259
(a capsule) relative to an oral solution after a 100mg or 50mg single dose and
to evaluate the effect of food on these formulations (n= 12 for each study).
Main Outcome Measures: The non-compartmental pharmacokinetic parame-
ters for plasma concentrations ofGLPG0259were determined, and a population
pharmacokineticmodel ofGLPG0259was developed to support the planning of
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the number and timing of the sparse samples to be taken per patient in the phase
II study. Safety and tolerability data are also summarized.
Results: The absorption of GLPG0259 was slow, with a decrease in the ab-
sorption rate with increasing dose, and there was decreased elimination, with
an apparent terminal elimination half-life of 26.0 hours. On the basis of
statistical analysis of variance, the exposure to GLPG0259 increased in pro-
portion to the dose over a 30–150mg single-dose range and a 25–75mg re-
peated-dose range. Between- and within-subject variability in GLPG0259
pharmacokinetics was low/moderate (coefficient of variation [CV] 16–30%).
After once-daily repeated dosing, steady-state plasma concentrations were
reached at between 5 and 8 dosing days, which is consistent with the long
apparent elimination half-life of GLPG0259. Food increased the bioavaila-
bility of GLPG0259 given in a solid dosage form. Co-administration of
GLPG0259 with a single dose of methotrexate 7.5mg did not result in any
change in the pharmacokinetic profiles of either GLPG0259 or methotrexate.
Conclusion: In summary, the investigation of safety/tolerability and pharma-
cokinetics in the early development phase showed that single and repeated
doses of GLPG0259 were safe and well tolerated. The most common adverse
event reported was mild gastrointestinal discomfort. The pharmacokinetics
characterized in healthy male subjects showed no major obstacles and sup-
ports a once-daily oral regimen in patients.
Introduction
Rheumatoid arthritis (RA) is a chronic auto-
immune inflammatory and joint degenerative
disease, which affects almost 1% of the adult
population worldwide, with onset classically occur-
ring between the ages of 30 and 50 years, and a
higher prevalence in women. The disease is char-
acterized by pain, stiffness, and restricted mobility
due to persistent symmetrical inflammation of the
synovial membranes of multiple joints, which ulti-
mately results in irreversible damage of the joint
cartilage and bone.[1-3]
Development of the disease involves an in-
flammatory response of the synovial membrane,
accompanied by infiltration of a variety of immune
cells, which leads to the build-up and mainten-
ance of a cytokine network. One of the cytokines
central to this network is tumor necrosis factor
(TNF), as is clearly demonstrated by the clinical
success of TNF blockers in treating RA. TNF
and other proinflammatory cytokines contribute
to cartilage and bone erosion by inducing release
of degradative enzymes, such as matrix metal-
loproteinases (MMPs), and stimulating the release
of receptor-activated NFkB-ligand (RANKL),
which triggers differentiation of hematopoeitic
cells into bone-resorbing osteoclasts. When left
untreated, the disease leads to significant dis-
ability associated with high economic costs.
In recent years, the therapeutic management of
patients with RA has undergone major evolution.
Up to 10 years ago, therapeutic approaches relied
on synthetic disease-modifying anti-rheumatic drugs
(DMARDs) such as methotrexate and sulphasala-
zine, which had only partial clinical benefit andwere
associated with significant toxicity. A considerable
advance in the effective treatment of RA came from
the introduction of the biologic therapeutics that
neutralize cytokines or their receptors (TNFa and
interleukin [IL]-6) or that inhibit cellular activation
(B-cell or T-cell activation).[4,5]
However, because of the high production
costs, inconvenience of parenteral administration,
increased risk of infections, and potential immu-
nogenicity of biologics, there is still a need for less
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expensive and orally administered drugs.[4] Hence,
the development of small-molecule inhibitors tar-
geting disease-relevant signal transduction path-
ways is being pursued by various companies.[6]
GLPG0259 is a small-molecule inhibitor of
mitogen-activated protein kinase–activated protein
kinase 5 (MAPKAPK5), a kinase enzyme that plays
a role in important inflammatory pathways. In-
hibition of MAPKAPK5 with GLPG0259 repre-
sents a novel mechanism of action in the treatment
of RA. MAPKAPK5 belongs to a family of mi-
togen-activated protein kinases that play an im-
portant role in several cellular processes, including
inflammation, proliferation, and differentiation.
MAPKAPK5 is involved in a transduction path-
way inRApatients that ultimately leads to secretion
of catabolic enzymes such as MMP1, which cause
damage to the bone and cartilage in these patients.
GLPG0259 is a potent inhibitor of MAPKAPK5,
and in vitro it reduces the release of several media-
tors of inflammation and bone degradation, such
as MMP1, MMP13, TNF, and IL6. After oral ad-
ministration in mice, GLPG0259 reduces paw in-
flammation aswell as bone destruction in themouse
collagen-induced arthritis (CIA) model of human
RA at a dose of 1mg/kg and higher. Even in mice
with late-stage CIA disease, GLPG0259 reduces
inflammation and bone destruction.
The main objectives of the phase I clinical
studies in early development were to characterize
the pharmacokinetics, tolerability, and safety of
GLPG0259 in healthy subjects, including the de-
velopment of a solid dosage form and the potential
for interaction of GLPG0259 with methotrexate
(the anchor drug in RA patients).
However, an exploratory phase II study in a
small number of RA patients with an insufficient
response to methotrexate showed no significant
clinical benefit of GLPG0259 compared with
placebo, and the development of GLPG0259 was
discontinued (Westhovens R et al., unpublished
data).[7]
Subjects and Methods
All studies were conducted in accordance with
accepted standards for the protection of subject
safety and welfare, and the principles of the
Declaration of Helsinki and its amendments, and
were in compliance with Good Clinical Practice.
Protocols and informed consents were approved
by the Ziekenhuis Netwerk Antwerpen (ZNA)
Institutional Review Board (Antwerp, Belgium).
All healthy participants gave written informed
consent prior to study initiation.
Study Designs
Study 1: First-in-Human, Single Ascending and
Multiple Oral Doses
This was a randomized, double-blind, placebo-
controlled, single-center study to evaluate the
safety, tolerability, and pharmacokinetics of single
ascending andmultiple oral doses of GLPG0259 in
healthy subjects. Eligible subjects (aged 18–50 years,
body mass index [BMI] 18–30kg/m2) were in good
health with no clinically significant deviation from
normal in terms of medical history, physical ex-
aminations, electrocardiograms (ECGs), or clinical
laboratory determinations. Subjects were excluded
from the study if they had medical history of ab-
normal platelet function or a history of a current
immunosuppressive condition.
The study was divided into two parts:
 Part 1 (n = 16 subjects): Single escalating dose
intake of GLPG0259 or matching placebo
(1.5–150mg) was studied in two cohorts of eight
subjects (active or placebo in a 3 :1 ratio) in an
alternating panel design. There was a minimum
7-day washout period between treatments for
each subject within a cohort and at least 3 days
for each dose increment between cohorts.
 Part 2 (n = 18 subjects): Multiple dose intakes
(20mg and 50mg once daily) of GLPG0259 or
a matching placebo over 5 days were studied in
two cohorts of nine subjects (active or placebo
in a 2 : 1 ratio). There was a minimum period
of 7 days between the two cohorts.
Treatment allocation was determined by a
computer-generated randomization schedule. Sub-
jects were admitted to the clinical unit on the even-
ing prior to dosing (day -1) and were confined until
24 hours after the last dose.
In both parts, GLPG0259 free-base solution
(1–10mg/mL in 40% [w/v] hydroxypropyl-X–
cyclodextrin, pH 3) or a matching placebo was
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given using a graduated syringe. A volume of
200mL of water was given to each subject im-
mediately at the time of dosing. Treatments were
administered after a standard breakfast (i.e. four
slices of whole-wheat bread, one slice of salami,
one slice of cheddar cheese, one tablespoon of
butter and jam, totaling 590 kilocalories) except
during the last dosing period of part 1, where the
treatment was administered after an overnight
fast to assess the food effect on GLPG0259 bio-
availability. Drinks were standardized to at least
1000mL of mineral water per day.
Blood samples for pharmacokinetics were
collected at regular intervals over 24 hours (part
1: 1.5–15mg; part 2: 20mg and 50mg on day 1),
4 days (part 1: 30–150mg), or 7 days postdose (part
2: 20mg and 50mg on day 5). Blood was collected
in tubes containing lithium heparinate as an
anticoagulant in order to obtain plasma for ana-
lysis of the concentrations of GLPG0259. Within
30 minutes after blood collection, the plasma was
separated in a refrigerated centrifuge (4–8C) for
10 minutes at approximately 1500 g, transferred
into two polypropylene tubes with at least 500 mL
of plasma per tube, and stored at -20C until
analysis. Three urine fractions were collected in
part 2 on days 1 and 5 over a 24-hour period to
determine the amount of GLPG0259 excreted in
urine. After homogenization and recording of the
total weight, two 10mL samples for the GLPG0259
assay were stored at or below -20C until analysis.
Study 2: Multiple Ascending Oral Doses and
Methotrexate Drug-Drug Interaction
This was a phase I, randomized, double-blind,
placebo-controlled, single-center study to eval-
uate the safety, tolerability, and pharmacokinetics
of oral multiple ascending doses of GLPG0259
given for 14 days to healthy subjects (n= 24), and
to get preliminary information on the potential
pharmacokinetic interaction between GLPG0259
and methotrexate. The criteria for subject eligi-
bility were the same as those listed for study 1.
A total of 24 healthy male subjects were ran-
domized into three cohorts of eight subjects dosed
orally once daily with either placebo orGLPG0259
25mg, 50mg, or 75mg (active or placebo in a 3 : 1
ratio). In addition, the subjects from the 50mg
cohort received one single dose of methotrexate
7.5mg on two occasions: 7 days prior to dosing
with GLPG0259 (on day -7) and on day 14 at the
same time as the last GLPG0259 dose.
GLPG0259 free base (10mg/mL in 40% [w/v]
hydroxypropyl-X–cyclodextrin, pH 3) or a match-
ing placebowas administered once daily for 14 days,
using a syringe, as for study 1. Subjects in the
50mg dose group were additionally administered
an oral dose of methotrexate 7.5mg (3 tablets
of Ledertrexate 2.5mg; Wyeth-Pfizer) on two
occasions. A dose of 4mg of folic acid (Folavit;
Kela Pharma NV) was administered 24 hours
after each methotrexate administration as a pre-
ventive measure for methotrexate toxicity. Folic
acid was administered after all safety and pharm-
acokinetic assessments had been done.
Blood samples for pharmacokinetics were
collected at regular intervals over 24 hours (on
days 1 and 13 [in the 50mg cohort only]) or over
7 days after the last dose on day 14 (i.e. up to day
21) to assess plasma concentrations of GLPG0259.
Blood sample handling was similar to that de-
scribed for study 1. For methotrexate (in the 50mg
cohort only), blood samples were collected at reg-
ular intervals over 24 hours (on day -7 and day 14)
in tubes containing lithium heparinate, in order
to obtain plasma, and were stored at -20C until
analysis.
Study 3: Oral Relative Bioavailability and the
Food Effect
This was a phase I, open-label, randomized,
three-period, three-treatment crossover study to
compare the oral bioavailability of a solid dosage
form of GLPG0259 (a capsule) relative to an oral
solution, and to evaluate the effect of food on
oral bioavailability of GLPG0259 formulated as
a capsule in healthy subjects (n = 12). The criteria
for subject eligibility were the same as those listed
for study 1.
The treatments consisted of an oral dose of a
50mg GLPG0259 free-base solution given after
an overnight fast (treatment A), a GLPG0259
fumarate capsule (equivalent to 50mg free base)
given after an overnight fast (treatment B), and
a GLPG0259 fumarate capsule (equivalent to
50mg free base) given 30minutes after the start of
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a high-fat, high-calorie breakfast (treatment C).
Each subject was administered treatments A, B,
and C in one of the two treatment sequences (i.e.
ABC orACB) determined by a computer-generated
randomization schedule. There was at least a 7-day
washout period between treatments for each sub-
ject. Subjects were admitted to the clinical unit on
the evening prior to dosing (day -1) and were con-
fined until 24 hours after the last dose.
For treatment A, GLPG0259 free base was
administered as 5mL of 10mg/mL in 40% (w/v)
hydroxypropyl-X–cyclodextrin (pH 3), using a
syringe. A volume of 235mL of water was given
to each subject immediately at the time of dosing.
Capsules to be administered for treatments B and
C were filled with 50mg of GLPG0259 as a fu-
marate salt. One capsule was given with 240mL
of water alone (treatment B) or after a high-fat,
high-calorie breakfast as described in the FDA
Guidance for Industry[8] (i.e. two eggs fried in
butter, two slices of bacon, two slices of toast
with butter, 113 g of hash brown potatoes, and
240mL of whole milk, totaling 800–1000 kilo-
calories). The subjects took the 50mg capsule
with 240mL of water, within 10 minutes after the
high-fat, high-calorie breakfast. The breakfast
had to start 30 minutes prior to administration of
the study drug, and the subjects had to eat their
breakfast within 20 minutes.
Blood samples for pharmacokinetics were col-
lected at regular intervals over 96 hours to assess
plasma concentrations of GLPG0259. Blood
sample handling was similar to that described for
study 1.
Study 4: Oral Relative Bioavailability
of Two Solid Dosage Forms
This was a phase I, randomized, open label,
two-period, two-treatment crossover study to com-
pare the oral bioavailability of two solid oral for-
mulations of GLPG0259 after single-dose intake in
healthy subjects (n= 12). The criteria for subject
eligibility were the same as those listed for study 1.
The two treatments consisted of an oral dose
of two fumarate capsules containing GLPG0259
(equivalent to 25mg free base) given exactly 30
minutes after the start of a high-fat, high-calorie
breakfast (treatment A) and a single free-base
pellet capsule containing GLPG0259 50mg given
exactly 30 minutes after the start of a high-fat,
high-calorie breakfast (treatment B). Each sub-
ject was administered treatments A and B in one
of the two treatment sequences (i.e. AB or BA)
determined by a computer-generated random-
ization schedule, with at least a 10-day washout
period between treatments. Subjects were admit-
ted to the clinical unit on the evening prior to
dosing (day -1) and were confined until 24 hours
after the last dose.
Capsules administered in fed conditions were
taken within 10 minutes after the high-fat, high-
calorie breakfast, as in study 3.
Blood samples for pharmacokinetics were
collected at regular intervals over 96 hours to
assess plasma concentrations of GLPG0259.
Blood sample handling was similar to that de-
scribed for study 1.
Safety Assessments
In all four studies, general safety was eval-
uated by the incidence of adverse events (AEs)
through non-leading questioning, clinical labor-
atory parameters (hematology, biochemistry,
and urinalysis), vital signs, 12-lead ECGs, and
physical examinations.
Bioanalytic and Pharmacokinetic Methods
GLPG0259
Plasma GLPG0259 concentrations were deter-
mined using a validated liquid-chromatography–
mass spectrometry/mass spectrometry (LC–MS/
MS) assay. In brief, the internal standard (deu-
terated GLPG0259; 20 mL at 0.25 mg/mL) was
added to plasma samples and then processed by
liquid–liquid extraction. The evaporated and re-
constituted samples were injected into a Sciex
API 4000 LC–MS/MS equipped with a short
high-pressure liquid chromatography (HPLC)
column. GLPG0259 was detected with multiple
reactionmonitoring. Quantificationwas performed
using peak area ratios and standard curves (with
1/x2 linear least-squares regression) prepared from
calibration standards. The lower limit of quantifi-
cation was 0.200ng/mL. The between- and within-
run precision for quality controls, expressed as
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coefficients of variation (CVs), were no greater
than 13.9% and 7.50%, respectively, with devia-
tions from nominal concentrations of no more
than 12.0%.
A method adapted from the plasma bioanalytic
method was used to determine the concentrations
of GLPG0259 in urine. The internal standard
(deuterated GLPG0259; 20mL at 0.5mg/mL) was
added to 20mL of the urine sample. The corre-
sponding solution was diluted 50-fold and injected
directly into a Sciex API 4000 LC–MS/MS. The
lower limit of quantification was 2.00ng/mL. The
within-run precision for quality controls, expressed
as the CV, was no greater than 6.7%, with devia-
tions from nominal concentrations of no more
than 6.5%.
Plasma GLPG0259 concentrations were ana-
lyzed by a non-compartmental method. The
maximum plasma drug concentration (Cmax) and
time to reach Cmax (tmax) values were observed
directly from the data. The terminal elimination
rate constant (lz) was determined by log-linear
regression analysis of the elimination phase. The
apparent terminal elimination half-life (t½,lz),
calculated as t½,lz =Ln2/lz, was reported only if
more than three datapoints were used for linear
regression to determine lz with an adjusted r2
value of ‡0.900. Area under the plasma concen-
tration–time curve (AUC) values over the col-
lection interval (AUCt), over the dosing interval
(AUCt), or extrapolated to infinity (AUC¥) were
determined using standard non-compartmental
methods (WinNonLin version 5.2 software;
Pharsight Corporation, Mountain View, CA,
USA). The relative bioavailability (Frel) was cal-
culated as the ratio between the AUCs for the test
formulations (fumarate capsules or free-base
pellet capsules) and the AUCs for the reference
formulations (solution or fumarate capsules)
from studies 3 and 4. After multiple dosing, the
accumulation of GLPG0259 was estimated as the
ratio between the steady-state AUCt and the day
1 AUCt (Rac(AUC)). The following urine para-
meters were determined after multiple dosing for
5 days (study 1 part 2): the amount of GLPG0259
excreted unchanged in urine (Ae24h), expressed as
a percentage of the dose, and renal clearance
(CLR) over 24 hours (CLR24h).
Methotrexate
Plasma methotrexate concentrations were de-
termined using a validated LC–MS/MS assay. In
brief, the internal standard (deuterated GLPG0259;
200mL at 25ng/mL) was added to plasma samples
and then processed by liquid–liquid extraction. The
evaporated and reconstituted samples were injected
into a Sciex API 4000 LC–MS/MS equipped with
a short HPLC column. Methotrexate was detected
with multiple reaction monitoring. Quantification
was performed using peak area ratios and standard
curves (with 1/x2 linear least-squares regression)
prepared from calibration standards. The lower
limit of quantification was 5.00 ng/mL. The be-
tween- and within-run precision for quality con-
trols, expressed as CVs, were no greater than 7.40%
and 8.16%, respectively, with deviations from
nominal concentrations of no more than 8.0%.
The plasma methotrexate concentrations were
analyzed by a non-compartmental method, and
the following parameters were assessed: Cmax,
tmax, t½,lz, AUCt, and AUC¥.
Statistical Analyses
All statistical analyses were conducted using
SAS version 9.1 software (SAS Institute Inc.,
Cary, NC, USA).
For the pharmacokinetic analyses of the four
clinical studies, the descriptive statistics analysis
included arithmetic means and CVs for Cmax,
AUC, t½,lz, Ae24h, and CLR24h; the medians and
ranges for tmax; and the geometric means and CVs
for Rac(AUC) and Frel.
Clinical safety was addressed by assessing AEs,
physical examinations, laboratory assessments,
ECGs, and vital sign results in a descriptivemanner.
Descriptive statistics and shift tables (according to
normal ranges) were calculated for each parameter
at every timepoint and in each treatment group.
A treatment-emergent AE analysis was performed.
The following inferential statistics were per-
formed for each study, with a statistical significance
level of p< 0.0500.
Study 1
Dose proportionality was tested on dose-normal-
ized and natural log–transformed GLPG0259
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parameters (Cmax normalized to a 1mg dose [Cmax/
dose] and AUC from 0 to 24 hours [AUC24h]
normalized to a 1mg dose [AUC24h/dose]) after
single fed dosing by means of mixed-effects ana-
lysis of variance (ANOVA) with the cohort and
dose as fixed effects and the subject (nested within
the cohort) as a random effect. In the case of a
significant dose effect being observed on the pa-
rameters listed above, comparison between doses
was performed using Tukey’s test. The tmax, being
a discrete variable, was analyzed using a non–
parametric Kruskal-Wallis test to assess the dose
proportionality.
For part 2, a mixed-effects ANOVA was per-
formed on natural log–transformed GLPG0259
parameters (Cmax/dose, AUC24h/dose, t½,lz,
Ae24h, and CLR24h) with the day, dose, and day-
by-dose interaction as fixed effects and the sub-
ject as a random effect. Dose proportionality for
Rac(AUC) was evaluated from the adapted mixed-
effects ANOVA of AUC24h/dose. A Wilcoxon–
Mann-Whitney non-parametric test was used to
assess the dose proportionality of tmax. The time
to reach steady state was assessed by visual inspec-
tion of the trough plasma drug concentrations as
well as by means of a mixed-effects ANOVA on
Ln-transformed GLPG0259 trough plasma drug
concentrations. Comparison between days was
performed using Tukey’s test.
The food effect was assessed using geometric
mean ratios of the observed pharmacokinetic
parameters (Cmax, AUC24h, AUC¥, and t½,lz) for
GLPG0259, with and without food, and the
corresponding 90% confidence intervals (CIs) for
the ratios. Calculation of 90% CIs for the geo-
metric mean ratios was based on a mixed-effects
model for the natural log–transformed parame-
ters, with the dietary condition as a fixed effect
and the subject as a random effect. A Wilcoxon–
Mann-Whitney non-parametric test was used to
assess the food effect on tmax.
Study 2
Dose proportionality of GLPG0259 pharm-
acokinetics and steady-state assessment were tested
using the same statistical model as described for
study 1 part 2. The effect of GLPG0259 on me-
thotrexate pharmacokinetics (day 14 versus day -7)
and the effect of methotrexate on GLPG0259
pharmacokinetics (day 14 versus day 13) were
separately assessed on natural log–transformed
parameters (Cmax, tmax, AUC, and t½,lz), using a
mixed-effects ANOVA model with the day as a
fixed effect and the subject as a random effect.
The geometric mean ratio (i.e. the point estimate)
of these pharmacokinetic parameters between
days 14 and 13 for GLPG0259 and between days
14 and -7 for methotrexate was estimated from
this model, using the least-squares mean (LSM)
together with the 90% CI.
Studies 3 and 4
For both studies, the comparison between
treatments was assessed on Ln-transformed pa-
rameters (Cmax, AUC24h, AUC¥, and t½,lz) by
means of a mixed-effects ANOVA. The point
estimate was calculated as the geometric mean of
the individual ratios of each parameter for the
test/reference treatments and expressed as a per-
centage. The 90% CI of the point estimates was
calculated using the mean square error of the
ANOVA. As tmax is a discrete variable dependent
on selected blood sampling times, the same com-
parisons were assessed using a non-parametric
test. The 90% non-parametric CIs for the treat-
ment differences were calculated.
Population Pharmacokinetic Model
A population pharmacokinetic model was de-
veloped with data from the three first phase I
studies (at the time of performing the population
pharmacokinetic analysis, study 4 had not been
performed yet), which included 54 subjects who
received the active treatment within the dose
range of 1.5–150mg on at least one occasion (n= 6
at 1.5, 5, and 15mg; n= 18 at 20–30mg; n= 24 at
50mg; n= 12 at 60–75mg and 100mg; n = 6 at
150mg) as fumarate salt capsules or free-base
solution given in either the fasted or fed state. The
model that was developed was then used to sup-
port the planning of the number and timing of the
sparse samples to be taken per patient in the
3-month phase II study. An exploratory graphical
analysis of the pharmacokinetics of GLPG0259
was performed. The graphical analysis consisted
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of plotting and comparing individual profiles and
the smoothes of dose-normalized profiles. Dose
linearity was evaluated by comparing the dose-
normalized profiles. The exploratory graphical
analysis plots were also scrutinized for food and
formulation effects. All analyses were performed
in accordance with appropriate guidelines.[9,10]
The population pharmacokinetic analyses were
performed using NONMEM version 7.1.0 soft-
ware.[11] The NONMEM model fitting used the
first-order conditional estimation (FOCE) method
with the interaction option throughout. S-Plus ver-
sion 6.2 software was used for exploratory graphical
analysis. R software (version 2.12.2)[12] was used for
evaluation of goodness of fit and model evaluation.
The programWinPOPT (version 1.2.1)[13] was used
to aid selection of the timing and number of samples
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Fig. 2. Mean (– standard error of the mean) plasma GLPG0259
concentrations after once-daily repeated oral dosing in fed healthy
subjects: (a) dosing for 5 days (n =6 per dose group); (b) dosing for
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Fig. 1. Mean (– standard error of the mean) plasma GLPG0259
concentrations after single oral doses in fed healthy subjects (n= 6
per dose group): (a) linear and (b) semi-logarithmic plots.
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Results
Safety and Tolerability
With the exception of a single subject who
discontinued study 1 because of a nephrolithiasis
while on placebo (reported as a serious AE
[SAE]), all subjects completed the studies. The
four studies showed a consistent pattern of AEs.
Nausea, abdominal discomfort, and loose stools
were the most frequently reported AEs, showing
a dose-related pattern of incidence and severity
from a dose of 50mg upward. The feeding status
or type of formulation had no influence on these
AEs. All other AEs were typical phase I environ-
ment events, such as somnolence, fatigue, head-
ache, oropharyngeal pain, and nasopharyngitis.
No clinically relevant trends or changes were ob-
served in the median laboratory and urinalysis
values over time. A single case of a mild alanine
aminotransferase increase was observed in a sub-
ject at the 75mg dose in the second study. Across
the four studies, no clinically relevant trends or
changes were observed in the median vital sign
values and ECG parameters over time. No treat-
ment-emergent abnormalities related to vital signs
or ECG parameters were observed in more than
one subject during the trials. None of the abnor-
malities related to vital signs or ECG parameters
were considered clinically relevant by the investiga-
tors. Aftermultiple dosing, themaximum tolerated
dose was established as being 50mg once daily.
GLPG0259 Single-Dose Pharmacokinetics (Study 1)
GLPG0259 plasma concentration–time data are
plotted in figures 1 and 2 (linear and semi-logarith-
mic plots), and the pharmacokinetic parameters are
listed in table I. At the three lowest doses (up to
15mg), lz could not be reliably estimated in most
of the subjects, because of insufficient datapoints
to characterize the terminal elimination phase. In
addition, for some subjects at the highest doses
(‡30mg), the AUC¥was poorly estimated, with an
extrapolated AUC from 24 hours to infinity that
represented more than 20% of the total AUC.
Consequently, the t½,lz and AUC¥ of these sub-





(ngh/mL)a t½,lz (h)a AUC¥(ngh/mL)a Cmax/dose(ng/mLmg)a AUC24h/dose(ngh/mLmg)a
1.5 0.314 [13] 2 [2–6] NC NC NC 0.209 [13] NC
5 1.02 [37] 2 [1–4] 17.2 [26]c NC NC 0.205 [37] 3.44 [26]c
15c 3.43 [23] 2 [2–6] 54.9 [18] NC NC 0.228 [23] 3.66 [18]
30 8.18 [28] 3 [1–7] 143 [34] 26.4 [18.6] 317 [44.6]d 0.273 [28] 4.78 [34]
60 16.1 [18] 4 [4–7] 284 [17] 25.9 [17.6] 745e 0.268 [18] 4.73 [17]
100 31.8 [29] 7 [4–7] 562 [22] 25.5 [17.9] 1310 [34.0]d 0.318 [29] 5.62 [22]
150 47.0 [21] 7 [4–7] 863 [21] 26.1 [6.75]f 2280 [2.00]f 0.313 [21] 5.75 [21]
ANOVA:
Tukey’s testg
p< 0.0001 p <0.0001
1.5, 5, 15mg
15, 30, 60, 100mg
30, 60, 100, 150mg
p <0.0001
5, 15mg
15, 30, 60, 100mg
30, 60, 100, 150mg
a Estimates are expressed as arithmetic mean [CV%].





g The differences between doses that are underlined with the same line were not statistically significant.
ANOVA= analysis of variance;AUC=area under the plasma concentration–time curve;AUC24h=AUC from0 to 24 hours;AUC24h/dose=1mg
dose–normalized AUC24h; AUC¥=AUC extrapolated to infinity; Cmax=maximum plasma drug concentration; Cmax/dose= 1mg dose–normal-
ized Cmax; CV= coefficient of variation; NC= not calculated; t½,kz=apparent terminal elimination half-life; tmax= time to reach Cmax.
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jects were not included in the summary statistics,
and no inferential statistical analysis was performed
on these two parameters. After a single oral ad-
ministration to healthy, fed subjects, GLPG0259
was absorbed slowly, with the median tmax increas-
ing with the dose from 2 to 7 hours (table I). The
terminal plasma elimination phase of GLPG0259
was parallel for doses ‡30mg and displayed a
monophasic profile (figure 1).
After single dosing, Cmax and AUC24h increased
proportionally within the 15–100mg and 30–150mg
dose ranges (table I). A significant dose effect on tmax
was observed, with a higher median value observed
at the two highest doses. Although no statistical
analysis was performed on t½,lz, no noticeable dif-
ference in this parameter was observed, with a mean
value of about 26.0 hours (range 25.5–26.4 hours).
GLPG0259 Repeated-Dose Pharmacokinetics
(Studies 1 and 2)
GLPG0259 plasma concentration–time data
are plotted in figure 2, and the pharmacokinetic
parameters are listed in table II. As was already
evident from the single-dose pharmacokinetics,
GLPG0259 was absorbed slowly, with a trend
toward an increase in tmax with increased dosing
(table II).
The steady-state GLPG0259 plasma concen-
tration was reached at between 4 and 8 dosing
days (figure 2, table III). After the last dose,
plasma elimination of GLPG0259 over time dis-
played a monophasic profile, with a t½,lz of
about 39 hours (range 35.0–41.6 hours). An ap-
proximate 2.5-fold increase in AUC24h and Cmax
of GLPG0259, similar for all doses, was observed
after once-daily dosing, which was consistent
with the long GLPG0259 t½,lz. After repeated
administration, GLPG0259 did not deviate from
dose proportionality, with AUC24h and Cmax in-
creasing in proportion to the dose within the
20–75mg dose range. Overall, the between-subject
variability in AUC24h and Cmax at steady state was
low/moderate (between-subject CV range 16–30%)
as was the within-subject variability, which was
derived from the square root of the mean square
error of the ANOVA (the CVs of AUC and Cmax
ranged between 9.8% and 20%; data not shown).
Excretion of unchanged GLPG0259 in urine
was rapid, with about 64–88% excreted within the
first 12 hours (data not shown). The Ae24h of
GLPG0259 represented 4.99% and 10.4% of the
dose administered after single and multiple dosing,
respectively, of 50mg of GLPG0259 for 5 days
(table II). The increase in the amount ofGLPG0259
excreted in urine between the first and last doses
mirrored the accumulation of GLPG0259 observed
in plasma. As a consequence, the CLR24h remained
constant between the first and last doses. At the
20mg dose, the increase in Ae24h between the
first and last doses (from 3.47% to 4.75%) was
Table III. Trough plasma GLPG0259 concentrations after once-daily repeated oral dosing in fed healthy subjects (n =6 per dose group)
Study Dose
(mg)
Trough plasma GLPG0259 concentrationsa ANOVA
Tukey’s testbDay 2 Day 3 Day 4 Day 5 Day 6 Day 8 Day 13
or 14
Study 1 20 3.81 [22.8] 6.72 [23.6] 7.66 [24.9] 7.62 [22.0] 8.13 [23.1] ND ND Day 2
Days 3, 5, 4, 6
50 8.57 [29.3] 13.6 [30.7] 16.1 [37.8] 16.7 [35.9] 18.6 [37.1] ND ND Days 2, 3
Days 4, 5, 6
Study 2 25 ND ND ND ND 9.09 [28.1] 9.97 [24.1] 10.2 [20.1] Days 6, 8, 14
50 ND ND ND ND 25.6 [30.1] 25.8 [27.1] 26.3 [30.0] Days 6, 8, 13
75 ND ND ND ND 27.6 [17.7] 35.1 [16.1] 34.9 [19.5]c Day 6
Days 8, 14
a Estimates are expressed as arithmetic mean [CV%].
b Tukey’s test (day comparison): the means are sorted in ascending order. The differences between days that are underlined with the same
line were not statistically significant.
c n= 5.
ANOVA = analysis of variance; CV = coefficient of variation; ND =no data.
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smaller than the increase in exposure (from 116 to
261ngh/mL), resulting in a slight decrease in CLR
with time (from 5.95 to 3.74L/h). However, these
differences were not statistically different and could
have been due to high variability in individual Ae24h
values (range 0.685–12.0%; CV 81.4%) compared
with AUC24h on day 5 (range 197–351ngh/mL;
CV 19.3%).
Drug-Drug Interaction with Methotrexate (Study 2)
GLPG0259 and methotrexate plasma concen-
tration–time data are plotted in figure 3, and
GLPG0259 and methotrexate pharmacokinetic
parameters with summary statistical analyses are
presented in table IV. Regarding GLPG0259, co-
administration of methotrexate 7.5mg did not
significantly alter the rate and extent of absorption
of GLPG0259, with point estimates for Cmax and
AUC24h of 102.67% and 102.11%, respectively.
Although the t½,lz of GLPG0259 could be esti-
mated on one occasion only, there was no mod-
ification of the elimination, as shown by the
superimposable elimination phases with or without
methotrexate in figure 3. It must be noted that even
if the study was not powered to analyze the influ-
ence of methotrexate on GLPG0259 pharmaco-
kinetics, using the 90% CI approach, the intervals
were narrow and their boundaries fell within the
80–125% bioequivalence range for both Cmax and
AUC24h (table IV). These results are explained
by the low/moderate within-subject variability in
GLPG0259 pharmacokinetics (<20%) and suggest
that a sample size of 12 subjects would be sufficient
to show bioequivalence between two treatments.
The plasma pharmacokinetic parameters of
methotrexate observed in this study were in
agreement with those reported previously for the
methotrexate 7.5mg dose.[14,15] When methotre-
xate was co-administered with GLPG0259 50mg,
the rate of absorption of methotrexate was slightly
but not statistically significantly decreased, with
a point estimate for Cmax of 89.63% (figure 3,
table IV). The extent of absorption (AUC¥) and
the elimination (t½,lz) of methotrexate were not
affected by GLPG0259, and their point estimates
were 118.22% and 110.64%, respectively.
Bioavailability and Food Interaction Studies
(Studies 1, 3, and 4)
As shown in figure 4a, food did not have an
impact on the rate and extent of absorption of
GLPG0259 given as 100mg of free-base oral sol-
ution, with aCmax of 31.8ng/mL (versus 31.0ng/mL
in the fasted state) and an AUC24h of 562ngh/mL
(versus 572ngh/mL in the fasted state) [table V],
and corresponding point estimates of 89.67% (90%
CI 74.71, 107.61) and 100.42% (90% CI 83.46,
120.83), respectively (table VI).
Compared with GLPG0259 free-base oral sol-
































































Fig. 3. Mean (– standard error of the mean) plasma concentrations
of (a) GLPG0259 and (b) methotrexate after administration of each
drug alone or in combination to fed healthy subjects (n= 6).
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of a single 50mg dose of GLPG0259 given as
the fumarate salt in capsule form in the fasted
state was decreased by about 45% (table VII).
No change in the absorption rate (tmax 6 versus
7 hours) or t½,lz (31.6 versus 29.6 hours) was noted.
This decrease in bioavailability was prevented by
dosing the GLPG0259 fumarate salt capsule in
the fed state (figure 4b). In such conditions, the
solid dosage form led to bioavailability com-
parable to that obtained with the GLPG0259
free-base oral solution administered in fasted con-
ditions, as shown by a Cmax of 15.2 ng/mL (versus
12.8 ng/mL) and an AUC¥ of 542 ngh/mL
(versus 536 ngh/mL) [table V].
Finally, a-head-to-head comparison of two
solid dosage forms was investigated after a single
50mg dose was given in the fed state as capsules
of GLPG0259 fumarate salt andGLPG0259 free-
base solid dispersion as coated pellets. The two
formulations compared well, as shown by Cmax
values of 20.4 ng/mLversus 19.8ng/mLandAUC¥
values of 713ngh/mL versus 670ngh/mL for the
free-base solid dispersion and fumarate salt, respec-
tively (table V), with corresponding point estimates
of 103.73% (90% CI 93.73, 114.81) and 107.80%
(90% CI 99.76, 116.50), respectively (table VI).
Even if these three studies were not powered to
compare formulations, using the 90%CI approach,
the interval boundaries for both Cmax and AUC
were close to or even fell within (study 4) the
80–125% bioequivalence range.
Population Pharmacokinetics of GLPG0259
The exploratory graphical analysis from study 1
(a single ascending dose) revealed that the elimi-
nation of GLPG0259 was independent of the
dose, but that the dose-normalized profiles were
not superimposable within the entire dose range
(1.5–150mg), that tmax occurred later at higher
doses, and that there appeared to be no influence of
food on the absorption of the solution formulation.
After multiple doses, steady-state GLPG0259
plasma concentrations were reached after 4–5 days.
The dose non-linearity observed after single dose
administration was not apparent after multiple
doses where a smaller dose range of 25–75mg was
given (data not shown). The graphical analysis
also showed that the Frel for GLPG0259 was lower
for the capsule formulation than for the solution
formulation, but that food increased the bio-
availability of the capsule to the same level as that
of the solution formulation. These findings are in
Table IV. Summary statistics for GLPG0259 and methotrexate pharmacokinetic parameters (n= 6)
Parameter GLPG0259 50mg Methotrexate 7.5mg
Day 13 Day 14 p-Value Point estimate
[90% CI]




44.4 [21] 45.8 [26] 0.5827 102.67
[93.79, 112.38]b
137 [22] 122 [20] 0.2740 89.63
[74.88, 107.27]b
tmax (h)
c 4 [2–7] 5.5 [2–7] 0.3750 1.5
[-1.0, 3.5]d
1.5 [1–2] 2 [1.5–4] 0.1875 1.0
[0.0, 3.0]d
AUC24h
(ngh/mL)a 849 [25] 870 [27] 0.2367 102.11[98.96, 105.36]b 639 [26]e 744 [17]e,f 0.0859 118.22[101.01, 138.36]b
t½,lz (h)
a NC 37.3 [9.4] 3.1 [14] 3.38 [12]f 0.1402 110.64
[98.39, 124.41]b
a Estimates are expressed as arithmetic mean [CV%].
b Point estimate and 90% CI of the least-squares geometric mean ratio (ANOVA).
c Estimates are expressed as median [range].
d Point estimate and 90% CI of the distribution-free signed rank test (Wilcoxon).
e AUC¥ for methotrexate.
f n = 5.
ANOVA = analysis of variance; AUC = area under the plasma concentration–time curve; AUC24h =AUC from 0 to 24 hours; AUC¥=AUC
extrapolated to infinity;CI = confidence interval;Cmax =maximum plasma drug concentration; CV = coefficient of variation; NC = not calculated;
t½,kz = apparent terminal elimination half-life; tmax = time to reach Cmax.
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good agreement with the conclusions drawn from
traditional pharmacokinetic analysis of the data
from these three studies.
Structural Model Development
Initially, one- and two-compartment disposition
models with simple first-order absorption were
compared. Inter-individual variability (IIV) was in-
cluded on all parameters, and a proportional re-
sidual error model was used. The two-compartment
model was superior. Next, food and formulation
effects were included on Frel, and the absorption
sub-model was expanded to a sequential zero-
then first-order absorption process for each of the
solution and capsule formulations. Ultimately,
only the duration of the zero-order input process
(D1) differed between the two formulations, fol-
lowed by the same first-order absorption-rate
constant (ka). The statistical model was refined in
the next step; IIV was included initially on all
structural model parameters but was not able to
be estimated on inter-compartmental clearance
(Q) and so was removed. Next, inter-occasion
variability (IOV) was introduced on Frel, ka, and
D1. The introduction of IOV on Frel and D1 re-
sulted in the IIV values for these two parameters
being extremely small and considered negligible,
and so IIV was removed. The proportional re-
sidual error model used at the start of the analysis




The final population pharmacokinetic model
was a two-compartment disposition model with
sequential zero- then first-order disposition. The
exploratory analysis had clearly shown that dose
was a potentially important covariate. The final
model contained an influence of dose on the pa-
rameters ka and Frel. Dose was included as a co-
variate on Frel as a power model; Frel increased
with increasing dose (figure 5b). Dose was also
included as a covariate on ka as a maximum effect
(Emax) model; ka decreased with increasing dose
up to 50mg and was then reasonably constant
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Fig. 4. GLPG0259 pharmacokinetic profiles after a single oral dose
of GLPG0259 given to healthy subjects as (a) free-base oral solution
in the fasted and fed states; (b) free-base oral solution in the fasted
state and fumarate salt capsules in the fasted and fed states; or
(c) fumarate salt capsules in the fed state and free-base solid dis-
persion capsules in the fed state.
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covariate, the parameterization used to describe
ka was altered to be equal to lz plus a constant
(flip-flop pharmacokinetics). As a result, t½,lz
could be calculated correctly.
Formulation had an effect on D1, which was
estimated to be 0.317 hours for the solution formu-
lation and 2.66 hours for the capsule formulation.
Formulation also had an effect on Frel, which was
estimated to be 0.489 of the Frel for the capsule
formulation. The presence of food (a high-fat
breakfast) was also found to influence Frel; Frel was
1.89 times greater in the presence of food with the
capsule formulation only. Consequently, food was
included as a covariate on Frel for the capsule for-
mulation only, and formulation was included as a
covariate on Frel and D1. IIV terms were included
on the apparent total body clearance (CL/F),
apparent volumes of distribution in the central
and peripheral compartments (V1/F and V2/F,
respectively), and ka. IOV was included on Frel,
D1, and ka. A proportional error model was used
to describe the residual variability. The para-
meter estimates for the final population pharm-
acokinetic model are presented in table VIII.
Table V. GLPG0259 pharmacokinetic parameters after a single oral dose of GLPG0259 given as various oral formulations to fasted or fed
healthy subjects (n =6 or 12 per formulation)
Parameter Study 1: 100mg (n= 6) Study 3: 50mg (n =12) Study 4: 50mg (n= 12)
Free-base oral solution Free-base
oral solution




Fasted Fed Fasted Fasted Fed Fed Fed
Cmax
(ng/mL)a
31.0 [35.2] 31.8 [28.6] 12.8 [23.9] 7.59 [41.2] 15.2 [37.2] 19.8 [33.6] 20.4 [32.9]
tmax (h)
b 7 [7–12] 7 [4–7] 7 [2–8] 6 [4–8] 6 [4–8] 6 [2–12] 6 [2–8]
AUC24h
(ngh/mL)a 572 [32.1] 562 [22.4] 220 [23.8] 118 [39.6] 223 [27.5] 294 [32.0] 323 [32.4]
t½,lz (h)
a NC 25.5 [17.9] 29.6 [14.1] 31.6 [8.64] 30.1 [16.5] 26.8 [10.3] 26.7 [10.6]
AUC¥
(ngh/mL)a NC 1310 [34.0]c 536 [17.0] 311 [40.8] 542 [23.2] 670 [35.3] 713 [34.3]
a Estimates are expressed as arithmetic mean [CV%].
b Estimates are expressed as median [range].
c n= 4.
AUC = area under the plasma concentration–time curve; AUC24h =AUC from 0 to 24 hours; AUC¥ =AUC extrapolated to infinity;
Cmax =maximum plasma drug concentration; CV = coefficient of variation; NC =not calculated; t½,kz = apparent terminal elimination half-life;
tmax = time to reach Cmax.
Table VI. Statistical analysis of the food effect on GLPG0259 pharmacokinetic parameters
Parameter Study Formulation Dietary
status
n p-Value Geometric mean
point estimate [90% CI]
AUC24h (ngh/mL) Study 1 Free-base oral solution Fasted (R) 6
Fed (T) 6 0.9609 100.42 [83.46, 120.83]
AUC¥ (ngh/mL) Study 3 Fumarate salt capsule Fasted (R) 12
Fed (T) 12 0.0015 183.39 [142.19, 236.53]
Cmax (ng/mL) Study 1 Free-base oral solution Fasted (R) 6
Fed (T) 6 0.2542 89.67 [74.71, 107.61]
Study 3 Fumarate salt capsule Fasted (R) 12
Fed (T) 12 0.0024 204.43 [148.25, 281.90]
AUC = area under the plasma concentration–time curve; AUC24h =AUC from 0 to 24 hours; AUC¥ =AUC extrapolated to infinity;
CI = confidence interval; Cmax =maximum plasma drug concentration; (R) = reference dietary status for calculation of the point estimate and
90% CI; (T) = test dietary status for calculation of the point estimate and 90% CI.
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The residual variability for the final model
(15.0%) was low and showed that the final pop-
ulation pharmacokinetic model described the
vast majority of the variability in the data. The
value of CL/F estimated for GLPG0259 was
79.3 L/h and was estimated with high precision
(relative standard error [SE] 4.0%). The estimate
of V1/F was 3030L and was also precise (relative
SE 4.4%). The values for CL/F and V1/F could be
used to obtain the t½,lz for GLPG0259, which
was calculated to be 26.5 hours. In general, all of
the parameters associated with the disposition of
GLPG0259 were estimated precisely (IIV around
20%). Parameters associated with absorption
were less precisely estimated (IIV and IOV ranged
between 20% and 75%), indicating that the ma-
jority of the overall variability in the pharmaco-
kinetics of GLPG0259 was due to absorption.
The value of ka at a dose of 50mg was calculated
to be 0.88/hour.
The goodness-of-fit plots for the final popu-
lation pharmacokinetic model of GLPG0259 are
shown in figures 6 and 7.
Model qualification of the final model, using a
visual predictive check (VPC) and a numerical
predictive check (NPC), showed that the model
was a good description of the data (figure 8).
Sample time optimizationwas performed using
the WinPOPT library two-compartment model
with first-order absorption. This is a simpler model
than the final population pharmacokinetic mod-
el, adjusted to reflect the structure of the library
model prior to performing the sample time opti-
mization. The absorption process was simplified
from the sequential zero- then first-order process
to a first-order process only, and the IOV terms
for D1, Frel, and ka were also removed. The ac-
tual parameter values used for the sample time
optimization are presented in table IX. The sim-
plified model retained the influence of dose on ka,
thus the value for ka (0.403/hour) is that calcu-
lated for a 50mg dose. The results of sample time
optimization are shown in table X.
The gold-standard design (six samples per sub-
ject after both the 7th and 84th doses) criterion
value was set at 100%. Further, the imprecision in
the estimated CL/F value under this design was
only 4.2%, indicating that the design was able to
estimate CL/F well.
The poor design (a single sample per sub-
ject after each of the 7th, 14th, 28th, 56th, and
84th doses, at 2 hours postdose) gave a criterion
value that was 0.026% of that for the gold-
standard design, and CL/Fwas estimated extremely
imprecisely.
Design no. 4, where a single sample was taken
per subject but at different times per visit and
always in the afternoon (thus at 5, 6, 7, 8, and
9 hours postdose across the visits) gave rise to a
criterion ratio of 4.1%, and CL/F was estimated
with 64.4% imprecision. Thus design no. 4 was
not very good but was a considerable improve-
ment over the poor design. Design no. 5 was
similar to design no. 4, but samples were allowed
Table VII. Statistical analysis of the formulation effect on GLPG0259 pharmacokinetic parameters
Parameter Study Dietary
status
Formulation n p-Value Geometric mean
point estimate [90% CI]
AUC¥ (ngh/mL) Study 3 Fasted Free-base oral solution (R) 12
Fumarate salt capsule (T) 12 0.0010 54.11 [42.21, 69.36]
Study 4 Fed Fumarate salt capsule (R) 12
Free-base pellet capsule (T) 12 0.1097 107.80 [99.76, 116.50]
Cmax (ng/mL) Study 3 Fasted Free-base oral solution (R) 12
Fumarate salt capsule (T) 12 0.0027 55.77 [42.49, 73.22]
Study 4 Fed Fumarate salt capsule (R) 12
Free-base pellet capsule (T) 12 0.5272 103.73 [93.73, 114.81]
AUC¥ = area under the plasma concentration–time curve extrapolated to infinity; CI = confidence interval; Cmax =maximum plasma drug
concentration; (R) = reference formulation for calculation of the point estimate and 90% CI; (T) = test formulation for calculation of the point
estimate and 90% CI.
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to be taken both in the morning and in the af-
ternoon, and the criterion ratio improved to 8.0%
and CL/F was estimated with 22.1% imprecision.
As can be seen in table IX, various designs were
tested, but the greatest improvement came when
the spread of the timing of the samples over the
dosing interval was as wide as possible across the
visits (design no. 8), and the criterion ratio was
25.8% and CL/F was estimated with 6.2% im-
precision. Allowing more than one sample to be
taken on one of the visits (design nos. 11 and 12)
did not improve the criterion ratio or improve the
precision with which CL/F was estimated, prob-
ably because a design with five samples per subjects
was already adequate as a sparse sample design.
Discussion
After single and daily repeated administration,
GLPG0259 was slowly absorbed and eliminated.
On the basis of a statistical ANOVA, the ex-
posure to GLPG0259 increased in proportion to
the dose over a 30–150mg single-dose range and
a 25–75mg repeated-dose range.
In the population pharmacokinetic model de-
veloped with data from the three first phase I
studies, the Frel for GLPG0259 increased with
increasing dose, while the ka decreased with in-
creasing dose up to 50mg and was then reasonably
constant. Conversely to the conclusion drawn from
the ANOVA on dose-normalized parameters,
these changes in Frel and ka detected during the
development of the population pharmacokinetic
model would be a sign of non–dose-proportional
pharmacokinetics. It is not unusual to observe de-
viation from dose proportionality within a dose
range as wide as 1.5–150mg. In addition, a popu-
lation approach is much more sensitive than
standard statistical analysis for finding and char-
acterizing dose non-linearity.[16] More data would
be needed, especially at higher dose levels, to refine
the model and the relation of ka and Frel to the
dose to draw definitive conclusions on the dose
linearity of GLPG0259 pharmacokinetics. The
most frequently reported AEs following repeated
administration with GLPG0259 were related to
gastrointestinal disorders (loose stools, nausea,
abdominal pain, or discomfort). These events,
reported only at doses of 50mg and higher, could
be explained by the residence time of GLPG0259
in the gastrointestinal tract. Indeed in a whole-
body autoradiographywith [14C]-radiolabeled com-
pound administered in a mouse model (3mg/kg
[14C]-GLPG0259), a huge amount of radioactiv-
ity was localized 4 and 8 hours postdose in the
small and large intestine contents, as well as in the
gallbladder, suggesting slow and incomplete ab-
sorption and/or intestinal secretion directly or via
the bile (data not shown). Apart from gastro-























Fig. 5. Influence of dose on (a) the first-order absorption rate con-
stant and (b) relative bioavailability in the final population pharm-
acokinetic model. Frel = relative bioavailability; ka= first-order ab-
sorption rate constant.
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intestinal disorders, no systemicAEs were reported
after repeated dosing with GLPG0259. Thus an
increase in Frel with increasing dose should not be
of concern as long as systemic exposure in humans
remains below the ‘no observed adverse effect
level’ (NOAEL) exposures in animal species.
Methotrexate is an antifolate usedwith varying
degrees of success in the treatment of cancer and
autoimmune diseases.[17] Low-dose pulse metho-
trexate has emerged as the anchor drug in patients
with RA because of its favorable risk-benefit
profile.[18] Methotrexate is mainly eliminated by
the kidney as intact drug, regardless of the route
of administration. Glomerular filtration is the
predominant pathway, with an additional active
secretory process via organic anion transporters
(OATs). Active biliary secretion also plays a role in
methotrexate elimination, with variable amounts
of methotrexate available for enterohepatic re-
circulation. Many drugs currently used in RA are
known to interact with methotrexate pharmaco-
kinetics: chloroquine reduces intestinal absorption;
non-steroidal anti-inflammatory drugs can lead to
a decrease in renal blood flow and glomerular fil-
tration, and can compete with drug transporters
for active renal tubular secretion; and calcium
folinate has been shown to shorten the mean resi-
dence time of methotrexate in the kidney and
Table VIII. GLPG0259 parameter estimates for the final population pharmacokinetic model







CL/F (L/h) [y1] 79.3 3.14 4.0 73.2, 85.5
V1/F (L) [y2] 3030 135 4.4 2766, 3294
ka for solution (/h) [y3] 5.01 2.81 56.1 -0.497, 10.5
Q (L/h) [y4] 22.4 3.94 17.6 14.7, 30.2
V2/F (L) [y5] 838 61.5 7.3 717, 958
Food effect on Frel for capsule [y6] 1.89 0.154 8.1 1.59, 2.20
Capsule effect on Frel [y7] 0.489 0.0327 6.7 0.424, 0.553
ka for capsule as a fraction of ka for solution [y8] 1 (fixed)
D1 for solution (h) [y9] 0.317 0.0953 30.1 0.130, 0.503
D1 for capsule (h) [y10] 2.66 1.10 41.3 0.506, 4.81
Frel dose power factor [y11] 0.165 0.0446 27.0 0.0780, 0.253
ka D50 (mg) [y12] 10.2 9.30 91.3 -8.05, 28.4
ka Emax (/h) [y13] 5.0 2.68 53.7 -0.266, 10.3
ka Hill coefficient [y14] 1 (fixed)
Statistical model
CL/F IIV [Z1] 0.0430a 0.0137 31.9 20.7
V1/F IIV [Z2] 0.0428 0.0185 43.2 20.7
ka IIV [Z3] 0.144 0.134 92.5 38.0
V2/F IIV [Z5] 0.0250a 0.0497 198.8 15.8
Frel IOV [Z8–11] 0.0415 0.00775 18.7 20.4
D1 IOV [Z12–15] 0.568 0.284 50.0 75.4
ka IOV [Z16–19] 0.188 0.0949 50.4 43.4
Residual error model
Proportional error [s1] 0.0224 0.000859 3.8 15.0
a A correlation between the IIV estimates for CL/F and V2/F was also included in the final model and was estimated to be 0.84.
CI = confidence interval; CL/F = apparent total body clearance; CV = coefficient of variation; D1 = duration of zero-order input (NONMEM data
file item); D50 = dose needed to obtain 50% of the effect; Emax =maximum effect; Frel = relative bioavailability; IIV = inter-individual variability;
IOV = inter-occasion variability; ka= first-order absorption rate constant;Q= inter-compartmental clearance; SE = standard error; sqrt = square
root; V1/F =apparent volume of distribution in the central compartment; V2/F = apparent volume of distribution in the peripheral compartment.
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liver.[15] GLPG0259 was eliminated by metabolism
as well as renal excretion. Total body clearance of
GLPG0259, predicted using allometric scaling
of intravenous data from several animal species
corrected for their maximum lifespan, as described
by Mahmood,[19] was moderate, with a value of
54L/h (data not shown). CLRdetermined in healthy
subjects accounts for about 9L/h of the total
body clearance. As reported previously, the pres-
ence of radioactivity in the gallbladder after [14C]-
GLPG0259 administration in a mouse model
may suggest the elimination of GLPG0259 or
metabolites via bile secretion and a possibility for
re-absorption and enterohepatic recirculation. As
GLPG0259 was intended to be developed for use
as a monotherapy or in combination with drugs
such as methotrexate, and taking into account
the common routes of elimination of both metho-
trexate and GLPG0259, it was of interest to get
preliminary information on the potential for drug-
drug interaction between these two compounds at























































Fig. 6. Goodness-of-fit plots: observed data are plotted on the y-axes, and population predictions [graphs (a) and (b)] and individual model
predictions [graphs (c) and (d)] are plotted on the x-axes. Graphs (a) and (c) are on a linear scale, and graphs (b) and (d) are on a logarithmic
scale. The dashed datalines are identity lines, and the thick solid datalines are smoothes through the data. The smooth lines lie very close to the
identity lines, for both the population and individual predictions, indicating that the structural model describes the data well. IPRED = individual
predictions; PRED = population predictions.
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analysis was performed on a small subset of sub-
jects (n= 6), no modification of the absorption or
the elimination of methotrexate was noted after
a daily dose of GLPG0259 50mg. The t½,lz values
for methotrexate estimated with and without
GLPG0259 were about 3.4 and 3.1 hours, respect-
ively. The range of boundary values for t½,lz re-
ported in the literature is quite large (6–69 hours).[17]
This variability may be partly related to differences
in blood sampling between studies. The terminal
log-linear phase cannot be determined accurately
if the sampling interval is too short and/or too few
blood samples are collected after 12 hours post-
dose.[15,17] Concerning GLPG0259, concomitant
dosing with methotrexate had no impact on its
bioavailability (Cmax and AUC24h).
Although theGLPG0259 free-base oral solution
showed good bioavailability, this formulation is
not easy to handle in long-term trials. Con-
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Fig. 7. Goodness-of-fit plots: (a) conditional weighted residuals versus population predictions; (b) absolute individual weighted residuals
versus individual predictions; (c) conditional weighted residuals versus time after dose; (d) conditional weighted residuals versus continuous
time. The dashed datalines are zero lines, and the thick solid datalines are smoothes through the data. The lack of trends in graphs (a), (c), and
(d) again indicates that the structural model describes the data well. The lack of a trend in the smooth line in graph (b) shows that the
proportional error model is appropriate for describing the residual error. CWRESI = conditional weighted residuals; IPRED = individual pre-
dictions; |IWRES| = absolute individual weighted residuals; PRED = population predictions.
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formwas envisaged. GLPG0259 free base is poorly
soluble in aqueous media, and its solubility de-
creases with increasing pH (<0.01mg/mL at pH 7).
Two approaches were developed in parallel to
overcome this low solubility and to improve
compound bioavailability after dosing in a solid
dosage form. The first approach was a salt screen-
ing, which resulted in the selection of the fumarate
salt for further formulation development work.
The water solubility of the GLPG0259 fumarate
salt, as compared with that of the free base, was
increased to 1.9–2.7mg/mL. The impact of the im-
provement in solubility was confirmed in a com-
parative bioavailability study in fasted dogs. In
that study, GLPG0259 fumarate salt (suspension
in 20% [w/v] hydroxypropyl-X–cyclodextrin, pH 3,
or as crystalline powder in capsule form) resulted
in plasma exposure similar to that of GLPG0259
free base in suspension in 20% acidified hydroxy-
propyl-X–cyclodextrin, but 4-fold higher plasma
exposure than that of GLPG0259 free-base crys-
talline powder in capsule form (data not shown).
In humans, administration of GLPG0259 fuma-
Table IX. GLPG0259 parameter estimates used for sample time
optimization
Parameter Estimate [%] IIV [%]
CL/F (L/h) 81.1 0.0661 [26]
V1/F (L) 3130 0.0573 [24]
V2/F (L) 821 0.0169 [13]
Q (L/h) 19.7 0 (fixed)
ka (/h) 0.403 0.184 [43]
Proportional residual variability 0.245 [49]
CL/F = apparent total body clearance; IIV = inter-individual variability;
ka= first-order absorption rate constant; Q= inter-compartmental
clearance; V1/F = apparent volume of distribution in the central
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Fig. 8. (a) Visual predictive check; (b) numerical predictive check (upper prediction interval limit); and (c) numerical predictive check (lower
prediction interval limit). In graph (a), the thick solid dataline shows the median of the observed data, and the dark gray shading shows the
model-predicted 95% confidence interval around the median. The dotted datalines are the limits between which 95% of the observed data are
found, and the light gray shading shows the model-predicted 95% confidence intervals around those limits. In graphs (b) and (c), the thin solid
datalines and white datapoints show the ratios between the actual and expected numbers of points for (b) the upper prediction interval and (c)
the lower prediction interval indicated on the x-axes, and the light gray shading shows the uncertainty of the model around the ratio of 1. The
dashed datalines are identity lines, with no difference between the actual and expected numbers.
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rate salt as a crystalline powder in capsule form
leads to 50% lower bioavailability than that of
GLPG0259 free base given as a solution in 40%
(w/v) hydroxypropyl-X–cyclodextrin, pH 3 (study 3).
The lower performance of the fumarate cap-
sule in humans than in dogs is explained by the
higher percentage of hydroxypropyl-X–cyclodex-
trin (40% versus 20%) in the liquid formulation,
which enhances GLPG0259 free-base solubility.
Concomitant food intake with the solid dosage
form prevents this decrease in bioavailability
by increasing the solubility further. The second
approach was the improvement of GLPG0259
solubility by physical modifications of the drug
substance – in particular, the development of solid
dispersion formulations with GLPG0259 free base
in an amorphous form homogenously dispersed in
a polymer matrix. The free-base solid dispersion as
a powder or pellets filled into capsules was tested in
fasted dogs, and both solid dispersion formula-
tions showed GLPG0259 plasma exposure similar
to that of the fumarate salt as a crystalline powder
in capsule form. Similar results were obtained in
humans (study 4).
In the Biopharmaceutical Classification System,
drugs are classified according to measurements
of solubility and permeability.[20] Regarding
GLPG0259, it is a poorly soluble compound,
with solubility that decreases with increased pH.
The absorption of GLPG0259 was not measured
in vivo in humans (there are no data after intra-
venous dosing), but its permeability assessed using
the well established in vitro system, based on the
human adenocarcinoma cell line Caco-2, was
good, with an apparent permeability coefficient
(Papp) of 12.4 10-6 cm/s and limited efflux (Papp
B2A/Papp A2B = 2). Thus on the basis of these
data, GLPG0259 could be classified as a class 2
compound, with in vivo drug dissolution then
being the rate-limiting step for its absorption. Salt
selection or solid dispersion development allows this
issue to be overcome and increases the solubility and
dissolution rate of GLPG0259, leading to an im-
provement in the bioavailability of the oral solid
dosage forms to be used in future clinical trials.
Conclusion
In summary, the investigation of safety/toler-
ability and pharmacokinetics in the early devel-
opment phase showed that single and repeated
doses of GLPG0259 were safe and well tolerated.
The most common AE reported was mild gas-
trointestinal discomfort. The pharmacokinetics
Table X. GLPG0259 parameter estimates used for sample time optimization
Design
number








Sampling days % of full
criterion
SE% on CL/F
Gold 2 full profiles 2 6 1, 2, 4, 8, 12, 24 7, 84 100 4.2
Poor 5 samples, all AM 5 1 2 7, 14, 28, 56, 84 0.026 363800093.4
4 5 samples, all PM 5 1 5, 6, 7, 8, 9 7, 14, 28, 56, 84 4.1 64.4
5 5 samples varying
between AM and PM
5 1 2, 3, 7, 8, 9 7, 14, 28, 56, 84 8.0 22.1
6 5 samples varying
between AM and PM: B
5 1 2, 4, 7, 9, 11 7, 14, 28, 56, 84 7.5 22.1
7 5 samples varying
between AM and PM: C
5 1 1, 5, 9, 11, 24 7, 14, 28, 56, 84 11.7 112.9
8 5 samples varying
between AM & PM: D
5 1 0, 1, 8, 22, 24 7, 14, 28, 56, 84 25.8 6.2
11 4 samples+2 samples
after the same dose
5 1 and 2
(1 group only)
2, 3, 7, 8, 9/9, 11 7, 14, 28, 56, 84 6.6 19.8
12 4 samples + 2 samples
after the same dose: B
5 1 and 2
(1 group only)
2, 3, 7, 8, 9/23, 24 7, 14, 28, 56, 84 13.8 23.1
a ‘B’, ‘C’, and ‘D’ refer to different sampling times/occasions.
AM =morning; CL/F =apparent total body clearance; PM = afternoon; SE = standard error.
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characterized in healthy male subjects showed no
major obstacles and supports a once-daily oral
regimen in patients.
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